about
Towards a new tuberculosis drug: pyridomycin - nature's isoniazidTowards a new combination therapy for tuberculosis with next generation benzothiazinonesRv2466c mediates the activation of TP053 to kill replicating and non-replicating Mycobacterium tuberculosis2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis.Leads for antitubercular compounds from kinase inhibitor library screensVirulence regulator EspR of Mycobacterium tuberculosis is a nucleoid-associated protein.Simple model for testing drugs against nonreplicating Mycobacterium tuberculosisLow levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.Tacrine-induced liver damage: an analysis of 19 candidate genes.Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion.Lead selection and characterization of antitubercular compounds using the Nested Chemical Library.Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrGStreptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsMechanism of action of 5-nitrothiophenes against Mycobacterium tuberculosis.Tuberculosis drugs: new candidates and how to find more.Discovery and Biosynthesis of Gladiolin: A Burkholderia gladioli Antibiotic with Promising Activity against Mycobacterium tuberculosis.Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis.Assessing the essentiality of the decaprenyl-phospho-d-arabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants.Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.Micrococcin P1 - A bactericidal thiopeptide active against Mycobacterium tuberculosis.Synthesis and antimycobacterial activity of 2,1'-dihydropyridomycinsIntracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes.Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.A druggable secretory protein maturase of Toxoplasma essential for invasion and egress.Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.MoS2/TiO2/SiNW surface as an effective substrate for LDI-MS detection of glucose and glutathione in real samples.In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosisIn vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosisGenome-wide definition of the SigF regulon in Mycobacterium tuberculosis.Sigma factor F does not prevent rifampin inhibition of RNA polymerase or cause rifampin tolerance in Mycobacterium tuberculosis.Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP.Whole cell screen based identification of spiropiperidines with potent antitubercular propertiesA rapid and sensitive HPLC–MS method for the detection of plasma and cellular rifampicinPyrrolomycins Are Potent Natural Protonophores
P50
Q27673316-72B903E9-9C5B-447B-9E19-C6AAD0FC8832Q27681604-7F887447-BC3D-4286-BA01-0BEA7148B66AQ27690464-5FD6AAA1-DC71-422C-89B4-2208A96C4F4BQ27696214-06411D54-8416-446A-929E-250DFEE62B7BQ27728459-A54E72CB-C1AF-4725-91AF-445476AF998CQ28487226-BB3FCDDA-3ED6-4363-9AED-F156BD03DA17Q29346755-E7EA1B3B-7E97-4CD9-94B7-63563900A61AQ30496706-F5C14EFD-07F6-4CCA-B0DE-5A46824EE5FBQ34352037-57DBDBAA-F060-40B0-8AE0-EB491D276D90Q34713811-F004815C-9F4E-4544-BA4F-7AA636EB78FEQ35316234-E40B699D-7472-4723-972B-1AB9157D7D56Q35584789-E895AFD7-CFB2-4098-81E2-117D4D71C090Q35637979-19C2FC45-1102-4D26-B4C6-6A995A8196F2Q35670107-7DBC7674-3D5F-4274-8730-458C51F6C08AQ36364079-D4FBE3E8-4702-4001-A1D4-CC1C4DCDB93FQ36877910-2CD17B18-E14F-4FE2-BA27-49B244AD9515Q37713071-D78192BE-A6EE-42C7-89A7-DFB2473363A1Q37894691-58078F7D-D771-47D3-AE85-ABAE676D9F2CQ38772710-1E4225CD-5FA5-441E-AC0B-816C86B66CEAQ38849126-7FB49ACB-499B-4138-AD6C-CE8F2B4C2708Q39015804-49180E73-957F-4F61-A87C-BECCF6644FFBQ39024963-D24B7AC1-C5B7-4440-8412-16D17EC9EB5FQ39345865-87919804-94D2-4C0F-95B3-3CBEEF239F27Q39461808-C7278489-8FA8-4FA2-B422-9511D0478A2FQ39779898-00F51988-92EB-41F6-9395-6873F42F120DQ39800309-F126B71D-A154-4258-BAD1-6672111E9025Q39801648-36004B3D-5B70-4EBC-BDB1-BF9EFA6464DFQ40051405-03753901-1FAD-4874-8732-3A4AE2A6E837Q40178008-D1DB7CB6-2F0A-43D6-8A06-66F112FFC685Q40196615-F45DCDE6-796E-410B-93F2-D77BBFB1F3D0Q41569899-A0841586-63A4-40ED-B7CC-1C762DACB73CQ41912190-4978C89E-6A5D-4B01-B16C-A60266C27912Q42111035-C782D20C-C19C-4720-ABC7-1EBB2CB2B475Q42137929-92D9D73C-9DDC-4842-AB77-FA44C35673E6Q42413646-C33AE3D4-458B-4BAB-90AF-158B6F9B3171Q46801300-996F626E-CCAA-43EB-9BBF-2F1CA6047B1AQ60920163-1BE93BC5-7290-432F-B72D-362C860FD3D2Q62744160-0B7D7E16-64B5-41B2-B093-B49072BD85ADQ92575635-6A412E04-0DE9-4596-9960-775894B77A1A
P50
description
researcher ORCID ID = 0000-0001-7315-1553
@en
wetenschapper
@nl
name
Ruben Hartkoorn
@ast
Ruben Hartkoorn
@en
Ruben Hartkoorn
@es
Ruben Hartkoorn
@nl
type
label
Ruben Hartkoorn
@ast
Ruben Hartkoorn
@en
Ruben Hartkoorn
@es
Ruben Hartkoorn
@nl
prefLabel
Ruben Hartkoorn
@ast
Ruben Hartkoorn
@en
Ruben Hartkoorn
@es
Ruben Hartkoorn
@nl
P106
P21
P31
P496
0000-0001-7315-1553